Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfusion-associated hepatitis B: past and present.

L B Seeff1

  • 1Veterans Administration Medical Center, Washington, DC.

Transfusion Medicine Reviews
|December 1, 1988
PubMed
Summary

Hepatitis B accounted for less than 25% of transfusion-associated hepatitis cases. Enhanced donor screening and blood supply changes have significantly reduced hepatitis B transmission risks in recipients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial.

Alimentary pharmacology & therapeutics·2010
Same author

The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy.

Journal of viral hepatitis·2008
Same author

Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity.

Oncogene·2006
Same author

Strategies for assessing the long-term consequences of Hepatitis C virus infection.

Minerva gastroenterologica e dietologica·2006
Same author

The natural history of chronic hepatitis C virus infection.

Clinics in liver disease·2004
Same author

Complementary and alternative medicine in chronic liver disease.

Hepatology (Baltimore, Md.)·2001

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Transfusion Medicine

Background:

  • Transfusion-associated hepatitis poses a significant public health concern.
  • Hepatitis B virus (HBV) is a primary etiological agent of transfusion-transmitted liver disease.
  • Donor screening strategies have evolved to mitigate viral transmission risks.

Observation:

  • Hepatitis B (HB) likely never exceeded 25% of transfusion-associated hepatitis cases, even pre-donor screening.
  • By 1988, routine HBsAg screening reduced HBV infection in blood recipients to below 10%, with exceptions in multiply transfused populations like hemophiliacs.
  • Eliminating paid blood donors proved more effective than HBsAg screening alone in reducing overall transfusion-associated hepatitis.

Findings:

  • Current screening protocols, including anti-HBc, ALT, and anti-HIV, are expected to further decrease HBV attack rates.
  • Newer viral inactivation methods may reduce HBV transmission in vulnerable hemophiliac populations.
  • The long-term outcomes of transfusion-associated Hepatitis B remain largely undetermined due to declining case numbers.

Implications:

  • The effectiveness of paid blood donor interdiction highlights the importance of blood source safety.
  • Continued vigilance and evolving screening technologies are crucial for minimizing transfusion-transmitted infections.
  • Future research requires re-evaluation of historical patient data to understand long-term Hepatitis B sequelae.

Related Experiment Videos